HealthMore in Health→
Oral GLP-1 candidate helps patients hold onto weight loss after injectable therapy
Key Takeaways
- Phase 3b data showed oral orforglipron preserved more prior weight loss than placebo after injectable therapy.
- Benefits were seen in participants previously treated with either tirzepatide or semaglutide.
- The study supports an oral maintenance strategy but did not compare switching with staying on injectables.
DE
DT Editorial Team··via nature.com
